Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Generic Central Nervous System Drugs Market Heading Into 2029?

In recent times, the xerostomia therapeutics market has experienced a consistent expansion. It is projected to increase from $2.14 billion in 2024 to $2.24 billion in 2025, displaying a compound annual growth rate (CAGR) of 4.7%. Reasons for this growth during the historical period include a rise in xerostomia cases within the elderly population, advancement in product research for xerostomia, boosting awareness concerning xerostomia-related merchandise, growing health conditions, and an increased prevalence of chronic illnesses.

It is predicted that the xerostomia therapeutics market will undergo a stable increase in the upcoming years, expanding to “$2.69 billion in 2029, with a 4.7% compound annual growth rate (CAGR).” This forecasted growth can be associated with the readily accessible economical medicines, the ever-growing incidence of oral health issues, heightened awareness among medical professionals, government policy initiatives, and the growing trend of medication use. Noteworthy trends to watch out for during the forecasted period include the rise in artificial saliva and saliva substitutes, advances in technology and product innovation, personalized and targeted therapies, telehealth and distant supervision, and the emergence of non-invasive therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

Which Factors Are Pushing The Generic Central Nervous System Drugs Market Forward?

The rise in mental health disorders is set to stimulate the expansion of the generic central nervous system (CNS) drug market in the future. These disorders cause significant impairment in a person’s cognitive abilities, emotional handling or behavioral patterns, often associated with distress or dysfunctional behavior in key aspects of life. Generic CNS drugs are pivotal in managing these disorders as they provide accessible and cost-effective treatment choices. For instance, the Health and Social Care Information Centre, a UK federal entity providing data, information, and computer systems for professionals, doctors, and administrators in the social and healthcare sectors, reported in November 2022 that the percentage of 17- to 19-year-olds presumed to have a mental disorder increased from 17.4% in 2021 to 25.7% in 2022. Consequently, the escalating prevalence of mental health disorders is fuelling the growth of the generic CNS drug market.

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

What Notable Trends Are Shaping The Direction Of The Generic Central Nervous System Drugs Market?

Major firms in the xerostomia therapeutics industry are innovating non-invasive, patient-centric treatments like oral sprays to meet the rising demand for efficient and convenient dry mouth management tools. Oral sprays specifically target and moisten dry mouth areas, providing immediate lubrication and relief in the needed areas. For instance, K Pharmaceuticals, a company established in India, released Aquoral in July 2023- a clinically tested oral spray, to mitigate dry mouth or xerostomia. Various elements such as medicines and diseases cause this condition leading to discomfort, chewing, swallowing troubles, and escalated oral health complications. Aquoral forms a continual protective shield over six hours in the mouth, which lessens the loss of moisture and improves comfort. This plant-derived lipid-based technology, Oxidized Glycerol Triesters (OGT), prevents the need for constant reapplications unlike traditional aqueous-based solutions, providing superior coverage.

Which Organizations Are Driving Progress In The Generic Central Nervous System Drugs Industry?

Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd., Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Generic Central Nervous System Drugs Industry?

North America was the largest region in the xerostomia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15700&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model